Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/en/publications/10256-a-randomised-phase-ii-study-investigating-durvalumab-in-addition-to-an-anthracycline-taxane-based-neoadjuvant-therapy-in-early-triple-negative-breast-cancer-clinical-results-and-biomarker-analysis-of-geparnuevo-study